Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
AssigneesYeda Research and Development Co. Ltd., The Board of Trustees of the Leland Stanford Junior University
InventorsRina Aharoni, Ruth Arnon, Nelson J. Chao, Paul G. Schlegel, Michael Sela, Dvora Teitelbaum
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.
Claims16
A method for preventing or treating graft-versus-host disease (GVHD) in a patient about to undergo bone marrow or organ transplantation or suffering from GVHD caused by bone marrow or organ transplantation, which comprises administering to said patient an effective amount of a synthetic random copolymer of average molecular weight 4,000-12,000, herein referred to as GLAT copolymer, said GLAT copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.2 parts of Lys to 4.0-6.0 parts of Ala to 1.0 part of Tyr.
Dependencies are inferred from the claim text.